Evidence determines access. Access determines value.
Pricing, market access, HTA and evidence strategy for biotech companies.
Sur Access connects clinical evidence with the access and commercial decisions that determine an asset's value — from development strategy through HTA, pricing, reimbursement and launch.
A strong FDA story is no longer enough.
Bridging the gap between scientific innovation and commercial value.
Since 2025, Europe's Joint Clinical Assessment (JCA) has become the real gatekeeper for premium pricing
(EU HTA Regulation (EU) 2021/2282 —
https://eur-lex.europa.eu/eli/reg/2021/2282/oj) — and under Most-Favored-Nation pressure, a weak European assessment now drags down the US price floor too. For an emerging biotech, an asset that looks like a blockbuster on FDA potential can lose most of its value if the evidence doesn't hold up to the JCA. That risk is fixable — but only while there's still time to act on it.
Built for emerging biotech
Roche and Novartis have floors of in-house HTA specialists. You don't, and you don't need them full-time. I'm the specialist you bring in for the questions that decide your value:
- Will your trial win a strong added-benefit rating?
- What price will it actually command across the EU-5?
- What is the asset really worth once JCA and MFN are priced in?
I connect the evidence to the value — the piece that your strategy cannot miss.
How I help
Global Pricing & Market Access
Pricing potential, access strategy, launch sequencing, international reference pricing and global price dynamics.
Evidence & HTA Strategy
Evidence gap analysis, comparator and endpoint strategy, PICO anticipation, subpopulation planning and regulatory–HTA integration.
EU HTA & JCA
JCA readiness, PICO strategy, comparative evidence planning, indirect comparisons and dossier support.
Swiss Pricing & Reimbursement
Swiss price strategy, APV/TQV, SL dossiers, reimbursement pathways, BAG engagement and early access
Our Partners Trust Our Approach
